RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced completion of enrollment in E-Tryton 150 and E-Tryton Benelux, two European registry studies of the company’s TRYTON Side Branch Stent™ System for the treatment of atherosclerotic lesions in the side branch at the site of a bifurcation.
